Wait Before buying - check if the support level will not be broken before buying, otherwise hold
Fundamental Analysis
Johnson & Johnson (NYSE:JNJ) began researching vaccine candidates in January, as soon as the COVID-19 sequence became available.
A Phase 1 clinical trial of the novel coronavirus vaccine is planned for September, with data regarding safety and efficacy available by the end of the year. If all goes accordingly, the vaccine could be ready “for emergency use” in early 2021.
As part of this commitment, Johnson & Johnson will scale up its manufacturing capacity in the U.S. and other countries in order to enable the supply of more than 1 billion doses of the vaccine when it is ready.
Fundamental Analysis
Johnson & Johnson (NYSE:JNJ) began researching vaccine candidates in January, as soon as the COVID-19 sequence became available.
A Phase 1 clinical trial of the novel coronavirus vaccine is planned for September, with data regarding safety and efficacy available by the end of the year. If all goes accordingly, the vaccine could be ready “for emergency use” in early 2021.
As part of this commitment, Johnson & Johnson will scale up its manufacturing capacity in the U.S. and other countries in order to enable the supply of more than 1 billion doses of the vaccine when it is ready.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.